Trial Profile
Intra-hepatic and systemic chemotherapy with or without antibody for patients with non-resectable liver metastasis from solid tumours.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cetuximab (Primary) ; Gemcitabine (Primary) ; Mitomycin (Primary) ; Oxaliplatin (Primary) ; Oxaliplatin (Primary)
- Indications Liver metastases; Solid tumours
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 20 Jul 2017 Status changed from recruiting to discontinued.
- 18 Jul 2011 New trial record